Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Rhea-AI Summary

Marinus Pharmaceuticals (NASDAQ: MRNS) announced its participation in key investor conferences in November and December. Leadership will present at the Jefferies London Healthcare Conference from November 18-19, featuring CEO Scott Braunstein and CFO Steven Pfanstiel. They will also host a Virtual Investor Event at the American Epilepsy Society's Annual Meeting on December 6. Additionally, one-on-one meetings will occur at the Jefferies Denver Healthcare Summit on December 16. Marinus focuses on innovative treatments for rare seizure disorders, including ongoing Phase 3 trials for ganaxolone.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following investor conferences in November and December.

12th Annual Jefferies London Healthcare Conference

• Date and Time: Available on demand starting Thursday, November 18, 3:00 a.m. ET through Friday, November 19, 12:00 p.m. ET
• Speakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer
• Webcast Link: https://wsw.com/webcast/jeff201/mrns/1865664

Marinus Pharmaceuticals Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting

• Date and Time: Monday, December 6, 1:00–2:30 p.m. ET
• Webcast Link: https://wsw.com/webcast/cc/mrns4/1448568

Jefferies Denver Healthcare Summit

• Date and Time: Thursday, December 16
• One-on-one meetings with Marinus leadership open only to Jefferies conference participants

About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005040/en/

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

484-253-6792

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

What is the date of the Jefferies London Healthcare Conference for Marinus Pharmaceuticals?

The Jefferies London Healthcare Conference will be available on demand from November 18, 3:00 a.m. ET to November 19, 12:00 p.m. ET.

Who will represent Marinus Pharmaceuticals at the investor conferences?

CEO Scott Braunstein and CFO Steven Pfanstiel will represent Marinus Pharmaceuticals at the conferences.

When is the Marinus Pharmaceuticals Virtual Investor Event?

The Marinus Pharmaceuticals Virtual Investor Event will take place on December 6 from 1:00 to 2:30 p.m. ET.

What is the focus of Marinus Pharmaceuticals?

Marinus Pharmaceuticals focuses on developing therapeutics for rare seizure disorders.

Which trials is Marinus Pharmaceuticals currently conducting?

Marinus is conducting Phase 3 trials for ganaxolone in conditions like CDKL5 deficiency disorder and tuberous sclerosis complex.